ArticleClinical & experimental metastasis2014
Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.
Article in Clinical & experimental metastasis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Prostatic Acid Phosphatase (PAP) Antibodies to Treat Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2026Article
- Comparison of bone mineral density between the tumour side and the healthy side in patients with malignant tumours of the long bones of the lower extremities: a prospective study.BMC musculoskeletal disorders · 2026Observational
- Review
- Transmembrane prostatic acid phosphatase: a therapeutic target in advanced prostate cancer.American journal of clinical and experimental urology · 2024Article
- Prostate cancer bone metastases biology and clinical management (Review).Oncology letters · 2023Review
- The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review.Frontiers in oncology · 2023Review
- Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer.Frontiers in endocrinology · 2023Article
- Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.Journal of translational medicine · 2022Article
- Mechanisms of Osteoblastic Bone Metastasis in Prostate Cancer: Role of Prostatic Acid Phosphatase.Journal of the Endocrine Society · 2019Review
- Prostatic Acid Phosphatase (PAP) Predicts Prostate Cancer Progress in a Population-Based Study: The Renewal of PAP?Disease markers · 2019Article
- Hallmarks of Bone Metastasis.Calcified tissue international · 2018Review
- Hypercalcaemia and hypocalcaemia: finding the balance.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Review
- Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases.Endocrinology · 2016Article
- EGF receptor ligands: recent advances.F1000Research · 2016Review
- A review of osteocyte function and the emerging importance of sclerostin.The Journal of bone and joint surgery. American volume · 2014Review
- Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function.Oncotarget · 2014Article
- Prostate cancer and bone: the elective affinities.BioMed research international · 2014Review
- Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Approximately 90 % of patients who die of prostate cancer (PCa) have bone metastases, often promoting osteoblastic lesions. We observed that 88 % of castration-resistant PCa (CRPC) bone metastases express prostatic acid phosphatase (PAP), a soluble secreted protein expressed by prostate epithelial cells in predominately osteoblastic (n = 18) or osteolytic (n = 15) lesions. Additionally, conditioned media (CM) of an osteoblastic PCa xenograft LuCaP 23.1 contained significant levels of PAP and promoted mineralization in mouse and human calvaria-derived cells (MC3T3-E1 and HCO). To demonstrate that PAP promotes mineralization, we stimulated MC3T3-E1 cells with PAP and observed increased mineralization, which could be blocked with the specific PAP inhibitor, phosphonic acid. Furthermore, the mineralization promoted by LuCaP 23.1 CM was also blocked by phosphonic acid, suggesting PAP is responsible for the mineralization promoting activity of LuCaP 23.1. In addition, gene expression arrays comparing osteoblastic to osteolytic CRPC (n = 14) identified betacellulin (BTC) as a gene upregulated during the osteoblastic response in osteoblasts during new bone formation. Moreover, BTC levels were increased in bone marrow stromal cells in response to LuCaP 23.1 CM in vitro. Because new bone formation does occur in osteoblastic and can occur in osteolytic CRPC bone metastases, we confirmed by immunohistochemistry (n = 36) that BTC was highly expressed in osteoblasts involved in new bone formation occurring in both osteoblastic and osteolytic sites. These studies suggest a role for PAP in promoting the osteoblastic reaction in CRPC bone metastases and identify BTC as a novel downstream protein expressed in osteoblasts during new bone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.